Table 2.

Expression and Content of Transcription Factors NF-κB p65, NF-κB p50, HIF-1α, HIF-2α in Disseminated Cancer Tissues of Kidney before (Untreated Group) and after Pazopanib Targeted Therapy (Pazopanib Treated Group)

Parameter, Relative units	n	Untreated group	Pazopanib treated group	Parameter	Untreated group	Pazopanib treated group
Transcription factors expression				Transcription factors content
NF-kB p65	33	3.1±1.5	0.98±0.66	NF-kB p65, Units/mg protein in well	9.8 (6.6-15.3)	4.6 (3.9-9.0)*
NF-kB p50	33	31.1±19.3	1.16±0.85	NF-kB p50, Units/mg protein in well	7.0 (5.12-20.62)	4.47 (3.34-6.33)*
HIF-1a	33	3.0±1.22	0.48±0.27	HIF-1a, Units/mg protein in well	6.2 (3.1-7.1)	1.0 (0.34-2.0)*
HIF-2a	33	17,8±10,9	0,37±0,23*	HIF-2a, pg/mg of protein	332,0 (246,0-551,9)	352,8 (300,0-1007,2)
VEGF, VEGFR2 and CAIX expression				VEGF, VEGFR2 and CAIX content
VEGF	33	4.9±1.9	0.3±0.2	VEGF, pg/mg of protein	16.6 (10.8-52.5)	9.2 (8.52-12.4)
VEGFR2	33	9.1±6.9	1.2±0.7	VEGFR2, pg/mg of protein	43.3 (23.5-62.5)	29.8 (19.1-41.6)
CAIX	33	11.5±6.13	3.7±3.7	CAIX, pg/mg of protein	246.9 (111.2-523.6	20.5 (14.8-81.5)*

^*- Level of significance compared to the patients untreated with pazopanib; p<0.05